Literature DB >> 10806995

Molecular mechanisms of action of antisense drugs.

S T Crooke1.   

Abstract

Given the progress reported during the past decade, a wide range of chemical modifications may be incorporated into potential antisense drugs. These modifications may influence all the properties of these molecules, including mechanism of action. DNA-like antisense drugs have been shown to serve as substrates when bound to target RNAs for RNase Hs. These enzymes cleave the RNA in RNA/DNA duplexes and now the human enzymes have been cloned and characterized. A number of mechanisms other than RNase H have also been reported for non-DNA-like antisense drugs. For example, activation of splicing, inhibition of 5'-cap formation, translation arrest and activation of double strand RNases have all been shown to be potential mechanisms. Thus, there is a growing repertoire of potential mechanisms of action from which to choose, and a range of modified oligonucleotides to match to the desired mechanism. Further, we are beginning to understand the various mechanisms in more detail. These insights, coupled with the ability to rapidly evaluate activities of antisense drugs under well-controlled rapid throughput systems, suggest that we will make more rapid progress in identifying new mechanisms, developing detailed understanding of each mechanism and creating oligonucleotides that better predict what sites in an RNA are most amenable to antisense drugs of various chemical classes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10806995     DOI: 10.1016/s0167-4781(99)00148-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  81 in total

1.  Post-transcriptional silencing of Notch2 mRNA in chronic lymphocytic [corrected] leukemic cells of B-CLL patients.

Authors:  Kaneez Fatima; Rehan Zafar Paracha; Ishtiaq Qadri
Journal:  Mol Biol Rep       Date:  2011-12-10       Impact factor: 2.316

2.  Molecular requirements for degradation of a modified sense RNA strand by Escherichia coli ribonuclease H1.

Authors:  Daniel R Yazbeck; Kyung-Lyum Min; Masad J Damha
Journal:  Nucleic Acids Res       Date:  2002-07-15       Impact factor: 16.971

3.  Specificity of short interfering RNA determined through gene expression signatures.

Authors:  Dimitri Semizarov; Leigh Frost; Aparna Sarthy; Paul Kroeger; Donald N Halbert; Stephen W Fesik
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-13       Impact factor: 11.205

4.  NMR structure of an alpha-L-LNA:RNA hybrid: structural implications for RNase H recognition.

Authors:  Jakob T Nielsen; Paul C Stein; Michael Petersen
Journal:  Nucleic Acids Res       Date:  2003-10-15       Impact factor: 16.971

5.  Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

Authors:  Holly B Kordasiewicz; Lisa M Stanek; Edward V Wancewicz; Curt Mazur; Melissa M McAlonis; Kimberly A Pytel; Jonathan W Artates; Andreas Weiss; Seng H Cheng; Lamya S Shihabuddin; Gene Hung; C Frank Bennett; Don W Cleveland
Journal:  Neuron       Date:  2012-06-21       Impact factor: 17.173

6.  Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity.

Authors:  Bryan A Kraynack; Brenda F Baker
Journal:  RNA       Date:  2005-11-21       Impact factor: 4.942

Review 7.  Strategies targeting telomerase inhibition.

Authors:  Huaping Chen; Yuanyuan Li; Trygve O Tollefsbol
Journal:  Mol Biotechnol       Date:  2008-10-28       Impact factor: 2.695

8.  RNA therapeutics: RNAi and antisense mechanisms and clinical applications.

Authors:  Jessica Chery
Journal:  Postdoc J       Date:  2016-07

9.  Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system.

Authors:  Qiang Hu; Marcel B Bally; Thomas D Madden
Journal:  Nucleic Acids Res       Date:  2002-08-15       Impact factor: 16.971

10.  Therapeutic potential of RNA interference in pain medicine.

Authors:  Ping-Heng Tan; Lin-Cheng Yang; Ru-Rong Ji
Journal:  Open Pain J       Date:  2009-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.